Showing 7251-7260 of 7518 results for "".
- Provectus Presents Data on PV-10 in Combination with Systemic Chemotherapyhttps://practicaldermatology.com/news/20121029-provectus_presents_data_on_pv-10_in_combination_with_systemic_chemotherapy/2459688/Provectus Pharmaceuticals, Inc. presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD. PV-10 is Provectus Pharmaceuticals' novel oncology drug design
- Dermatologist Launches Rx Rebates, LLChttps://practicaldermatology.com/news/20121029-dermatologist_launches_rx_rebates_llc/2459690/Joel Bain Herron, MD, a dermatologist with Northeast Dermatology & Cosmetic Surgery Center, LLC in Gahanna, OH, founded Rx Rebates, LLC, a technology company. The website Rx_Rebates.com will be a mobile accessible site with a searchable database of digital versions of branded prescription rebate car
- Health-Conscious Women 60% More Likely to Prefer Expensive Brand-Name Drugshttps://practicaldermatology.com/news/20121025-health-conscious_women_60_more_likely_to_prefer_expensive_brand-name_drugs/2459691/The consumer market research firm Scarborough analyzed "Health-Conscious Women," defined by Scarborough as American adult women who agree that they go to the doctor regularly for checkups, generally feel they eat right, and follow a regular exercise routine. Health-Conscious Women make up 16 percent
- TURO SKIN System Launchedhttps://practicaldermatology.com/news/20121018-turo_skin_system_launched/2459701/Founder and CEO John Renucci, MD, created TURO SKIN, a simplified skincare system for men, which has now been released. The collection offers solutions for face, shave, hair, and body. TURO SKIN products are available online at www.turoskin.com an
- New Fractionated Skin Resurfacing Module Enhances RF Laser Treatmentshttps://practicaldermatology.com/news/20121017-new_fractionated_skin_resurfacing_module_shortens_rf_laser_treatments/2459704/The PixelRF fractionated skin resurfacing module from Alma Lasers, Inc. uses proprietary InMotion Refractive Radiofrequency Micro Plasma Technology, which both ablates and heats the skin through controlled, focused delivery of energy without using disposables. The PixelRF was recently added to Alma'
- OIG Report: CMS Fails to Lessen Medicare Financial Losseshttps://practicaldermatology.com/news/20121012-oig_report_cms_fails_to_lessen_medicare_financial_losses/2459709/CMS failed to satisfy the legal requirements developed to lessen financial losses to Medicare, despite the agency's notification of the almost 14,000 Medicare beneficiaries whose health identities were compromised in 14 security breaches between Sept. 23, 2009, and Dec. 31, 2011, according to a repo
- Revance Regains Rights to Its Botulinum Toxinshttps://practicaldermatology.com/news/20121009-revance_regains_rights_to_its_botulinum_toxins/2459713/Revance Therapeutics, Inc. announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 Injectable Botulinum Toxin Type A.
- Strathspey Crown Hosts Founders Summithttps://practicaldermatology.com/news/20121002-strathspey_crown_hosts_founders_summit/2459717/Strathspey Crown recently hosted its Founders Summit & Retreat at Pelican Hill in Newport Beach, CA. The event gathered approximately 50 of the top physicians from elective healthcare and national leaders from government, healthcare, and f
- Jurlique Offers Holiday Discountshttps://practicaldermatology.com/news/20121002-jurlique_offers_holiday_discounts/2459718/Jurlique released holiday gift sets featuring full-sized product at a 30 to 40 percent savings. The products include: Age-Defying Trio, of Jurlique Purely Age-Defying Serum, Purely Age-Defying Ultra Firm and Lift Cream, and Skin Balancing Face Oi
- Janssen to Develop, Commercialize JAK Inhibitor For Immunological Diseaseshttps://practicaldermatology.com/news/20121002-janssen_to_develop_commercialize_jak_inhibitor_for_immunological_diseases/2459720/Janssen Biotech, Inc. entered into a license agreement with Astellas Pharma Inc. for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor. ASP015K is currently in Phase 2b development as a once-daily oral treatment for mod